Covid-19 roundup: Tiny sam­ple size leads FDA to turn down Rigel's EUA; Seat­tle biotech to co-de­vel­op mR­NA vac­cine in South Ko­rea

Four months af­ter Rigel an­nounced pos­si­ble Phase II re­sults for its Covid-19 treat­ment, the FDA has deemed the sam­ple size too small and in­suf­fi­cient for an emer­gency use au­tho­riza­tion, the com­pa­ny an­nounced Fri­day.

The Phase II tri­al of fos­ta­ma­tinib, which has pre­vi­ous­ly been ap­proved by the FDA as a sec­ond-line ther­a­py for throm­bo­cy­tope­nia, treat­ed just 59 pa­tients. Right now, a larg­er Phase III tri­al in hos­pi­tal­ized pa­tients is un­der­way to ex­am­ine the ef­fi­ca­cy of fos­ta­ma­tinib in hos­pi­tal­ized pa­tients with mild-to-se­vere Covid-19 com­pli­ca­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER